ClinicalTrials.gg
RecruitingNCT06938867Updated Oct 8, 2026

Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant

A Phase 1/2 interventional study of SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli and Placebo 10 mL in E Coli Infections and Allogenic Transplant Patients, sponsored by SNIPR Biome Aps.. Recruiting at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by SNIPR Biome Aps. · Phase 1/2, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Dec 2024, registered Apr 2025).
  • Started Dec 2024; still recruiting 1 year 11 months later.
Updated Oct 8, 2026Start date movedPrimary completion moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Escherichia coli Infections with a site in United States — 6 open to participants now, 7 under way, none of them phase 3. Escherichia coli Infections · United States.

Planned enrollment
14th of 29
66 · median 65
Started
2024
with 2 others
Phase 1/2
2 of 38
1 open now
Registered
37th of 38
by date

Among the 38 studies in Escherichia coli Infections with a site in United States, this one is the 14th largest by planned enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2024, is one of 2 in phase 1/2, and was the 37th registered.

Escherichia coli Infections

100 studies on the registry are indexed under Escherichia coli Infections; 21 are open to participants now.

Browse Escherichia coli Infections studies →

Open to participants now

6 of the 38 studies in Escherichia coli Infections with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Escherichia coli Infections studies recruiting now, 7 (58%) set no upper age limit and 4 (33%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Escherichia coli Infections with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1b/2a study in allogenic hematopoietic stem cell transplant patients to investigate the safety, PK, PD and preliminary efficacy of multiple oral administrations of SNIPR001 when given concomitantly with SoC levofloxacin. The study consists of two parts. Part 1 will include 24 randomized and dosed patients. Part 2 will be added with amendment 3 and will include 42 randomized and dosed patients. Thus, approximately 66 patients will be randomized 1:1 to oral dosing of SNIPR001 or matching placebo, to be taken concomitantly with SoC levofloxacin prophylaxis. Subjects will be followed until 100 days post allo-HSCT transplant.

Read the detailed description

Patients scheduled for allo-HSCT will be pre-screened for the presence (in the gut) of FQR E. coli cultured from a perianal swab. Part 1 has been completed and Part 2 has been initiated.

03

Conditions studied

  • E Coli Infections
  • Allogenic Transplant Patients
04

Who can participate

The criteria were revised on the registry on Oct 8, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥18 years of age at the time of consent.
  2. Patient is able and willing to provide written prior to any study-related procedure.
  3. Confirmed diagnosis of any hematologic .
  4. Planned to undergo an hematopoietic stem cell transplant.
  5. Patient is scheduled to receive fluoroquinolone (levofloxacin) prophylaxis.
  6. Colonized with Fluoroquinolone resistant E. coli (patients will be pre-screened for the presence of at least 1 Fluoroquinolone resistant E. coli colony [cultured from a perianal swab] performed at the local hospital lab, qualitative assessment +/-).
  7. Female patients must be of non- (surgically sterile or menopausal for at least 1 year) or agree to use a highly effective method, per local standard, while receiving treatment with SNIPR001 and for 28 days after the last dose of SNIPR001. Male patients must utilize highly effective contraceptive precautions for the duration of SNIPR001 dosing and for 28 days after the last dose of SNIPR001.
  8. Female patients of childbearing potential must have a negative serum pregnancy test at Screening and a negative serum or urine test on Day -2 prior to SNIPR001 dosing.
  9. Are willing to comply with all scheduled visits, laboratory tests, and other study procedures, including drinking the study medications, in the opinion of the Investigator.

Exclusion criteria

Exclusion Criteria:

  1. Use of any treatment (approved or product) considered to interact with the study drug, or which might impact the outcome of the study within 14 days (or 5 half-lives of the approved or investigational product, whichever is greater) prior to the first administration of study drug, as judged by the Investigator.
  2. Use or planned use of any antibiotics with intrinsic activity against E. coli in the gut (e.g., beta-lactam antibiotics) between Pre-Screening and until the end of the SNIPR001/placebo treatment period, with the exception of TMP-SMX and levofloxacin.
  3. Have known or allergy to any component of SNIPR001, levofloxacin and/or Alka-Seltzer treatment.
  4. Unwilling or unable to comply with the requirements of this Protocol, including providing stool samples.
  5. Female patients who are pregnant or lactating.
  6. Have abnormal liver enzymes ( [ALT] or aspartate aminotransferase [AST] >2 × [ULN] or total >1.5 × ULN).
  7. Have hepatic disease associated with impaired liver function.
  8. Have a history of Achilles tendinopathy or tendon rupture.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
66 participants (estimated)

Study arms

  • Active comparator
    SNIPR001 Active

    33 patients on SNIPR001 (BID for up to 30 days)

    Biological: SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli

  • Placebo comparator
    Placebo

    33 patients on Placebo (BID for up to 30 days)

    Other: Placebo 10 mL

Interventions

  • BiologicalSNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli

    SNIPR001 is a live biotherapeutic product

  • OtherPlacebo 10 mL

    Placebo 10 mL matching to SNIPR001 will be administered.

06

What researchers measure

Primary outcomes

  1. To assess the safety and tolerability of SNIPR001 in all patients who receive SNIPR001 or placebo in combination with standard of care (SoC) levofloxacin prophylaxis

    1. Incidence and severity of adverse events (AEs), treatment-emergent adverse events (TEAEs), and serious adverse events (SAEs), based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 5 (NCI CTCAE v5.0). AEs involving graft versus host disease (GvHD) will be graded according to the International Bone Marrow Registry Severity Index. 2. Time to neutrophil recovery (defined as the 1st day of ANC ≥0.5x109/L for 3 consecutive days) 3. Incidence of non-relapse mortality (NRM) 4. Incidence of all-cause mortality 5. Incidence of primary graft failure and secondary graft failure 6. Incidence of acute graft versus host disease (aGvHD) 7. Incidence of Clostridioides difficile (C. difficile) diarrhea 8. Median number of days from transplant to onset of neutropenic fever

    Time frame: Day 30 and 100 for endpoints 1-7 and 1-2 weeks for endpoint 8

Secondary outcomes

  1. To assess the pharmacodynamics (PD) of SNIPR001 in all patients who receive SNIPR001 or placebo in combination with SoC levofloxacin prophylaxis

    Proportion of patients with an increase in E. coli relative abundance in stool

    Time frame: Baseline and last day of dosing

  2. To assess the pharmacodynamics (PD) of SNIPR001 in all patients who receive SNIPR001 or placebo in combination with SoC levofloxacin prophylaxis

    Change in E. coli relative abundance in stool

    Time frame: Day-2 to end of dosing

  3. To assess the pharmacodynamics (PD) of SNIPR001 in all patients who receive SNIPR001 or placebo in combination with SoC levofloxacin prophylaxis

    Change in E. coli absolute abundance

    Time frame: Day-2 to end of dosing

  4. To assess the pharmacokinetics (PK) of SNIPR001 in all patients who receive SNIPR001 or placebo in combination with SoC levofloxacin prophylaxis

    Recovery of SNIPR001 from first dose of randomized treatment through 7 days after last dose randomized treatment in stool, blood and urine based on the number of plaque-forming units (PFUs) per gram in stool, and the number of PFUs per milliliter in blood and urine.

    Time frame: From first dose of randomized treatment through 7 days after last dose of randomized treatment in stool, blood and urine

  5. To assess the preliminary efficacy of SNIPR001 in all patients who receive SNIPR001 or placebo in combination with SoC levofloxacin prophylaxis

    * Proportion of patients with E. coli bloodstream infections (BSIs) assessed from the first dose of randomized treatment through 30 days after transplant. * Proportion of patients with gram-negative BSIs only, assessed from first dose of randomized treatment through 30 days after transplant. * Proportion of patients with gram-positive BSIs only, assessed from first dose of randomized treatment through 30 days after transplant. * Total BSIs assessed from first dose of randomized treatment through 30 days after transplant. * Incidence and number of neutropenic fever episodes from first dose of randomized treatment through 30 days after transplant. * Incidence and number of patients receiving broad-spectrum antibiotics on suspicion of a bloodstream infection

    Time frame: From the first dose of randomized treatment through 30 days after transplant.

07

Study locations

8 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Dec 2024 (actual). Primary completion is estimated for Oct 2027, 34 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: start Feb 2025 → Dec 2024, primary completion Apr 2026 → Oct 2027 and completion Apr 2026 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2025
First posted
Apr 22, 2025
StartActual
Dec 4, 2024was Feb 2025
Primary completionEst.
Oct 2027was Apr 2026
CompletionEst.
Oct 2027was Apr 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 1 site removed
Show 3 added (3 United States)
  • Johns Hopkins University · Baltimore, United States
  • Dana Farber Cancer Institute · Boston, United States
  • Memorial Sloan Kettering Cancer Center · New York, United States
Show 1 removed
  • John Hopkins University · Baltimore, United States
Oct 8, 2026
Start date
Feb 25, 2025→Dec 4, 2024
Oct 8, 2026
Primary completion
Apr 1, 2026→Oct 2027
Oct 8, 2026
Study completion
Apr 1, 2026→Oct 2027
Oct 8, 2026
Enrollment
24→66
Oct 8, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedHave known hypersensitivity or allergy to any component of SNIPR001, levofloxacin and/or Alka-Seltzer Gold treatment.
Oct 8, 2026
Sponsor
Collaborators added: U.S. Health and Human Services and Biomedical Advanced Research and Development Authority·The European Commission's DG Health Emergency Preparedness and Response Authority (DG HERA) and KfW Development Bank·Italy's Ministry of Economy and Finance·CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator)·Novo Nordisk Foundation; collaborators removed: Bill and Melinda Gates Foundation·Department of Health and Social Care, UK·Biomedical Advanced Research and Development Authority·German Federal Ministry of Education and Research
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    3 sites added, 1 site removed
    Show 3 added (3 United States)
    • Johns Hopkins University · Baltimore, United States
    • Dana Farber Cancer Institute · Boston, United States
    • Memorial Sloan Kettering Cancer Center · New York, United States
    Show 1 removed
    • John Hopkins University · Baltimore, United States
    Start date Feb 25, 2025→Dec 4, 2024
    Primary completion Apr 1, 2026→Oct 2027
    Study completion Apr 1, 2026→Oct 2027
    Enrollment 24→66
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedHave known hypersensitivity or allergy to any component of SNIPR001, levofloxacin and/or Alka-Seltzer Gold treatment.
    Sponsor Collaborators added: U.S. Health and Human Services and Biomedical Advanced Research and Development Authority·The European Commission's DG Health Emergency Preparedness and Response Authority (DG HERA) and KfW Development Bank·Italy's Ministry of Economy and Finance·CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator)·Novo Nordisk Foundation; collaborators removed: Bill and Melinda Gates Foundation·Department of Health and Social Care, UK·Biomedical Advanced Research and Development Authority·German Federal Ministry of Education and Research
    + 5 other changes: verification date, registry dates, oversight details, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06938867
Lead sponsor
SNIPR Biome Aps.
Collaborators
U.S. Health and Human Services and Biomedical Advanced Research and Development Authority, The European Commission's DG Health Emergency Preparedness and Response Authority (DG HERA) and KfW Development Bank, Italy's Ministry of Economy and Finance, CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), Wellcome Trust, Novo Nordisk Foundation
Responsible party
Sponsor
First posted
Apr 22, 2025
Start date
Dec 4, 2024
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Oct 8, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion